Anyone comparing options here runs into the same obstacle within about ten minutes: the question of insurance and ketamine: what is and is not covered looks straightforward until you try to answer it with real numbers. This guide sets out what is actually established, what varies between providers, and what to establish before committing to anything, written as continuous explanation rather than a checklist, because the reasoning is what transfers to your own situation.
Pairing sessions with structured psychological support follows directly from the mechanism, which makes its absence a substantive gap rather than a stylistic one. A clinic that agrees to treat anyone who asks, without reference to what has already been tried, has replaced clinical judgement with a booking system. Nothing about the United States changes that. Anyone comparing the United States programmes will find this decisive: commercial insurance seldom reimburses off-label intravenous administration, though the associated psychiatric evaluation is sometimes billable and worth asking about specifically. A history of psychosis or a bipolar diagnosis changes the risk calculation substantially, which is why a thorough intake asks about family psychiatric history and not only personal history. That is as true in the United States as anywhere else in the country. The information gap in the United States is not about whether ketamine treatment exists locally but about how to tell two local programmes apart.
Preparation shapes the experience more than most people expect. Clinics typically ask patients to avoid solid food for several hours beforehand, largely because of nausea, and to arrange a ride home, because driving is off the table for the remainder of the day. Beyond the logistics, the psychological preparation matters: going in with a settled expectation that the dissociative period is temporary, expected and monitored tends to make it far less alarming than encountering it cold. People who have discussed in advance what they will do if they feel frightened, and who know that the infusion can be slowed or stopped, generally describe a calmer experience than those who have not.
How the pieces fit together in practice
Knowing in advance that the dissociative period is temporary, expected and monitored tends to make it considerably less frightening than encountering it unprepared. The honest summary is that the short-term findings are encouraging and the long-term picture remains genuinely unsettled. Read carefully, it says that what people looking at the United States providers usually want is the operational detail, and that is precisely what clinic marketing tends to omit. Dosing for mood indications sits far below anaesthetic levels, typically calculated near 0.5 milligrams per kilogram of body weight and delivered slowly across about forty minutes.
The the United States comparison only becomes useful once this is clear. The mechanism is where ketamine departs from the antidepressants most people have already tried. Conventional selective serotonin reuptake inhibitors work primarily on monoamine systems and typically need four to six weeks before any effect is assessable. Ketamine acts on the glutamate system, principally as an antagonist at the N-methyl-D-aspartate receptor, and the downstream cascade it appears to trigger involves a surge in brain-derived neurotrophic factor and a measurable increase in synaptic connections in regions associated with mood regulation. Researchers describe this as a window of heightened neuroplasticity. The clinically useful framing is that ketamine may open a period during which the brain is more amenable to change, which is precisely why the therapeutic work done around the infusion matters as much as the infusion.
Why this question is harder than it should be
Solid food is usually restricted for several hours beforehand, largely to limit nausea during administration. Screening should cover cardiovascular history, personal and family history of psychosis or bipolar disorder, hepatic function, substance use history and current medications. The open question in the field is durability, which is why the maintenance conversation belongs in the first consultation rather than the seventh week. Transient elevation in blood pressure and heart rate is expected, which is the reason monitoring runs continuously rather than at intervals. The the United States listings on this page are organised so that this is checkable rather than assumed.
Esketamine, marketed as Spravato, occupies a different regulatory position that is routinely blurred in advertising. It is the S-enantiomer of ketamine, delivered as a nasal spray, and the FDA approved it in 2019 for treatment-resistant depression in adults used alongside an oral antidepressant, then in 2020 for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behaviour. Because it carries a Risk Evaluation and Mitigation Strategy, it can only be given at certified treatment centres, the patient must be observed for at least two hours afterwards, and they cannot drive until the following day. That is the entire practical difference for most people: esketamine is approved, insurable more often than not, and inconvenient; generic intravenous ketamine is off-label, usually paid out of pocket, and more flexible in how it is dosed.
The underlying facts, stated once and clearly
In the United States the same rule applies: ketamine is a Schedule III controlled substance, which formally recognises a potential for misuse and shapes how responsible programmes are structured. The trial evidence is real and also limited: studies tend to be small, follow-up periods short, and blinding is notoriously difficult when the dissociative effect is obvious to participants. It is the first thing to establish about any the United States programme. Appointment timing decides whether a course is compatible with employment, which is why the availability of early or late slots is more consequential than it sounds. It is worth carrying that into every conversation with a the United States provider. That holds in the United States as it does everywhere: integration, the structured work of making sense of a session afterwards, is the element most often missing from purely procedural clinics.
Set aside the United States for a moment, because the general position comes first. Ketamine has been in continuous clinical use since the United States Food and Drug Administration approved it as a general anaesthetic in 1970, which makes it one of the better characterised drugs in modern medicine from a safety standpoint. What is new is not the molecule but the dose and the intention behind it. Anaesthetic dosing renders a person unconscious for surgery; the subanaesthetic dosing used in mood work is a fraction of that, typically calculated at around 0.5 milligrams per kilogram of body weight delivered slowly over roughly forty minutes. At that level the person stays awake, breathing on their own, able to speak and to signal discomfort. The half century of anaesthetic safety data is genuinely reassuring about the drug itself, and it is also not the same thing as long-term safety data for repeated low-dose psychiatric use, which is a younger and thinner body of evidence.
What varies between providers and why it matters
Uncontrolled hypertension is treated as a serious caution for a straightforward physiological reason, and a programme that does not check blood pressure before dosing has skipped a step. Dissociation is the effect people ask about most: a sense of distance from the body, altered time perception and sometimes visual distortion, typically peaking partway through and resolving within half an hour of the infusion ending. Provider backgrounds in this field vary more than in almost any other corner of medicine, which is why credentials repay a closer reading than usual. The induction course is the part everyone discusses; what happens after it is the part that determines the real cost and the real commitment. Patients researching the United States providers run into this constantly. A dose calculated against body weight and adjusted across a course reflects a different philosophy from one held constant regardless of what the previous session produced.
The the United States comparison only becomes useful once this is clear. A standard induction course in most American clinics runs to six sessions delivered over two to three weeks, though the number is a convention inherited from early trial protocols rather than a figure settled by comparative research. Some people are offered four; some programmes run to eight. What happens after induction is the genuinely unresolved part of the field. Response, where it occurs, is often not permanent, and many patients move onto a maintenance schedule of a single session every two to six weeks. Any clinic that presents six infusions as a complete and finished course without discussing what maintenance might look like, and what it might cost over a year, is describing half the treatment.
What to do next
Applied to the United States, the point is this: for anyone whose decision turns on cost, asking whether a provider offers esketamine as well as intravenous administration is among the higher-value questions available. Read against the the United States market, telehealth has a legitimate role here for consultation, screening, follow-up and integration therapy, and it materially improves access for people far from a metropolitan clinic. For anyone weighing options in the United States, the clinics that treat this as a psychiatric treatment rather than a procedure tend to build psychological support into the protocol rather than offering it as an upsell. A consultation that moves quickly from hello to a package price has skipped the assessment that determines whether treatment is appropriate at all. Patients researching the United States providers run into this constantly. Cost is the constraint that settles the question for a large share of people, which makes the reluctance to publish prices worth noticing. It is worth carrying that into every conversation with a the United States provider.
What follows applies to the United States and to every other market, and it is the part worth reading slowly. Comparing clinics is difficult because the variables that matter are not the ones displayed on the website. Two facilities can charge similar prices and offer materially different care. The questions that separate them are who is physically present during the session and what their credential is, whether monitoring is continuous or intermittent, how the dose is determined and whether it is adjusted between sessions, what the plan is if a person does not respond after the induction course, whether psychiatric care is coordinated with an existing prescriber, and what integration support exists. Those answers can be obtained in one phone call, and the willingness to give them plainly is itself informative.
Putting this to use
The logistics of an induction course are what quietly determine whether people finish treatment or abandon it partway through. The infusion can be slowed or stopped if someone becomes distressed, and knowing that in advance is itself a meaningful part of preparation. Any programme presenting six sessions as a complete and finished treatment, without discussing maintenance, has described half of what is involved. In practice this means anyone searching for treatment in the United States meets the same wall of interchangeable clinic websites, all promising personalised care and none explaining what that means operationally. Ketamine acts on the glutamate system rather than the monoamine pathways targeted by conventional antidepressants, which is the likely reason its timeline differs so sharply.
Treatment decisions of this kind belong to a person and the clinician who knows their history. What a directory can usefully do is make sure nobody walks into that discussion missing something they needed.
This page is general information, not medical advice, and no directory can assess whether a treatment is appropriate for an individual. Ketamine is a controlled substance with genuine risks, and its use for mood disorders is off-label apart from esketamine, which holds FDA approval for treatment-resistant depression under a restricted programme. Decisions about treatment should be made with a qualified clinician who knows your full history. If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988 in the United States, or go to your nearest emergency department.